Clinical trial · Interventional
Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
NCT01054001CI-TRIAL-00005382SILRALPunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators try to investigate the benefit of early administration (immediately after urethral catheter removal) of sildenafil after nerve-sparing RALP for 3 months. The investigators will compare the potency rates up to 2 years after nerve-sparing RALP in men with on- demand sildenafil 100mg dosing from the early postoperative period (immediately after urethral catheter removal) with from the delayed postoperative period (3 months after RP).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sildenafil 100mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Early
- description
- men with on- demand sildenafil 100mg dosing from the early postoperative period
- interventionNames
- Drug: sildenafil 100mg
- type
- ACTIVE_COMPARATOR
- label
- Delayed
- description
- men with on- demand sildenafil 100mg dosing from the delayed postoperative period
- interventionNames
- Drug: sildenafil 100mg
Primary outcomes (1)
- measure
- patterns of recovery of erectile functions after nerve sparing RALP in men with on- demand sildenafil 100mg dosing from the early postoperative period (using IIEF-5)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Patients with agree to participate with the study * Korean male subjects aged 50 years or older with clinically localized prostate cancer * Preoperative potent men (IIEF-5 score 17 or more than 17) * Patients in a stable, heterosexual relationship with a single partner for at least the past six months * Suitable for nerve sparing indication Exclusion Criteria: * Genital anatomical deformities that would significantly impair erection * Other sexual disorders (e.g. hypoactive sexual desire) that are considered to be the primary diagnosis when there is a coexisting diagnosis of erectile dysfunction. * Known raised prolactin level (\>3 times the upper limit of the normal range) or low free testosterone level (confirmed to be \>20% below the lower limit of the normal range on blood collected between 09:00 and 11:00 hours). * Major psychiatric disorder (including major depression or schizophrenia) that is not well controlled on treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.